Effect of Intermittent Hypoxia in Healthy Individuals
Launched by SHIRLEY RYAN ABILITYLAB · Dec 28, 2020
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The use of acute intermittent hypoxia (AIH), has been demonstrated, through human and animal studies, to be an effective way of increasing spinal motor excitability and strengthening residual synaptic connectivity. AIH utilizes short duration (\<2 min) exposures to reduced oxygen levels (\~10% inspired oxygen), with alternating exposures to air with normal oxygen levels (\~21% inspired oxygen).
Previous publications demonstrate that AIH is a safe and effective intervention to modify motor function in individual with chronic incomplete spinal cord injuries. The use of AIH has been shown to ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • No history of neurologic injury or progressive neuromuscular disorder
- • Individuals ages 18-70 years old
- • Must be medically stable with no history of cardiovascular instability, congestive heart failure or stroke
- • Not currently (\>2 weeks) on any medications related to spasticity
- • No history of Sleep apnea
- • Not a current smoker
- • Able to comply with protocol/study requirements
- Exclusion Criteria:
- • Recent change in the use of narcotic, anti-inflammatory or pain medication
- • unstable medical conditions or any other clinical observation that may affect the candidate's performance, health, safety or the ability to participate in the study determined by the treating therapist or coordinating staff
- • Active participation in another movement research study or therapy program
- • Anti-spasticity drug injection less than 3 months prior to beginning treatment
- • Musculoskeletal pain that interferes with participation in study
- • Women who are currently, may be, or planning on becoming pregnant
- * for fMRI participation, participants will be excluded if they have:
- • Metal fragments in eyes or face
- • Implantation of any electronic devices such as (but not limited to) cardiac pacemakers, cardiac defibrillators, cochlea implants, or nerve stimulators
- • Vascular surgery
- • Claustrophobia
- • Body piercing or tattoos
About Shirley Ryan Abilitylab
Shirley Ryan AbilityLab is a leading research and rehabilitation institute dedicated to advancing the science of physical medicine and rehabilitation. Based in Chicago, Illinois, the organization integrates clinical care, research, and education to enhance the quality of life for individuals with disabilities and chronic conditions. Known for its innovative approach, Shirley Ryan AbilityLab conducts clinical trials that aim to develop and evaluate cutting-edge therapies and technologies, fostering a collaborative environment that bridges the gap between laboratory research and patient care. Through its commitment to excellence, the institute strives to empower patients and improve outcomes in rehabilitation medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
William Rymer, PhD
Principal Investigator
Shirley Ryan AbilityLab
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials